Teva, IBM team to further develop Watson Health Cloud

JERUSALEM and CAMBRIDGE, Mass. — Teva and IBM Watson Health announced Thursday that the pharmaceutical company had been chosen as IBM’s first Foundational Life Sciences partner for the Watson Health Cloud. 

Teva will use the Watson Health Cloud — an open-source platform for physiciancs, insurers and other health and wellness professionals — as a preferred global tech platform and will use it as a way of designing solutions for patients with chronic conditions. The two companies will also create joint research team that will use big data and machine learning technology to develop therapeutic solutions and disease models.

“Teva is actively exploring the e-health evolution with a strong focus on fulfilling unmet and emerging patients' needs,” Teva Pharmaceuticals’ SVP and CIO Guy Hadari said. “The IBM Watson Health Cloud provides a strong foundation on which we can realize this vision.” 

Watson is a computing platform that can interact in natural language, process huge amounts of data and learn from each interaction by uncovering insights and patterns. Teva will work to expand Watson Health Cloud’s capabilities and develop solutions to issues like drug musuce and adherence by drawing nsights from existing data.

“By building on the Watson Health Cloud, we believe Teva will be in a unique position to put the best information and insights in the hands of physicians, care teams and patients, to empower treatment optimization for individuals and populations across the spectrum of acute and chronic conditions,” Hadari said. “Watson holds promise to provide Teva with better insights, real-time feedback and options for clinicians to consider to improve patient care.”